Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Hazard Ratio
100%
Kidney Outcomes
100%
Adverse Cardiovascular Events
100%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
100%
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
100%
Antihyperglycemic
66%
Risk Reduction
50%
SARS-CoV-2 Infection
50%
Major Adverse Cardiovascular Events
33%
Major Adverse Kidney Events
33%
United States Department of Veterans Affairs
16%
Anemia
16%
Myocardial Infarction
16%
Survival Analysis
16%
Acute Kidney Injury
16%
Healthcare Database
16%
Baseline Characteristics
16%
In-hospital Outcomes
16%
Inverse Probability Weighting
16%
EGFR Decline
16%
Absolute Risk Reduction
16%
Kidney Events
16%
Injury Hazards
16%
Cardiovascular Risk Factors
16%
End-stage Kidney Disease
16%
Medicine and Dentistry
Hazard Ratio
100%
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Cardiovascular System
100%
Infection
50%
Cardiovascular Disease
33%
Veterans Affairs
16%
Anemia
16%
Myocardial Infarction
16%
Apoplexy
16%
End Stage Renal Disease
16%
Acute Kidney Injury
16%
Survival Analysis
16%
Risk Reduction
16%
Median Follow Up
16%
Pharmacology, Toxicology and Pharmaceutical Science
Sodium Glucose Cotransporter 2 Inhibitor
100%
SARS Coronavirus
100%
Infection
50%
Cardiovascular Disease
33%
Anemia
16%
Heart Infarction
16%
Acute Kidney Failure
16%
End Stage Renal Disease
16%
Cerebrovascular Accident
16%